Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 43

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 43
---
 Government Regulation

| ● | NewGenIvf operates in a highly regulated industry and must comply with a significant number of complex and evolving requirements. Any lack of requisite approvals, licenses, or permits applicable to NewGenIvf’s business may have a material and adverse impact on NewGenIvf’s business, financial condition, and results of operations. |
| ● | Advertising or offering of gender selection services in certain jurisdictions in which NewGenIvf operates could expose NewGenIvf and its directors and executive officers to significant legal and regulatory risks, including potential penalties.                                                                                        |
| ● | Changes in NewGenIvf’s effective tax rate or tax liability may have an adverse effect on its results of operations.                                                                                                                                                                                                                        |
| ● | NewGenIvf’s reported financial results may be adversely affected by changes in accounting principles generally accepted in relevant jurisdictions.                                                                                                                                                                                         |
| ● | If NewGenIvf’s estimates or judgments relating to its critical accounting policies prove to be incorrect, its results of operations could be adversely affected.                                                                                                                                                                           |
| ● | NewGenIvf is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability and harm its business, financial condition and results of operations.                                                                                      |

<div align='center'>23</div>

Risks Related to this Best Efforts Offering

| ● | This is a best efforts offering, no minimum number or dollar amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans.    |
| ● | An active trading market for the Class A Ordinary Shares may not be maintained and the trading price for the Class A Ordinary Shares may fluctuate significantly.                                      |
| ● | You will experience immediate and substantial dilution in the net tangible book value of the Class A Ordinary Shares purchased.                                                                        |
| ● | The trading price of the shares of the Class A Ordinary Shares has been and is likely to continue to be highly volatile, and purchasers of the Class A Ordinary Shares could incur substantial losses. |
| ● | We may use the proceeds of this offering in ways with which you may not agree.                                                                                                                         |

Recent Developments 2025 Debt Financing On April 1, 2025, the Company entered into a new Securities Purchase Agreement (“2025 Securities Purchase Agreement”) with certain investors named therein (collectively, the “Buyers”), pursuant to which, amongst other things: (i